<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03751059</url>
  </required_header>
  <id_info>
    <org_study_id>TWM</org_study_id>
    <nct_id>NCT03751059</nct_id>
  </id_info>
  <brief_title>NSAID vs Steroid in Trabeculectomy Wound Management</brief_title>
  <official_title>An Investigator-Initiated Multicenter Prospective Clinical Trial to Examine the Efficacy of Peri-operative NSAID vs Steroid Treatment in Trabeculectomy Wound Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cindy Hutnik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Glaucoma Research Society of Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ivey Eye Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the efficacy of steroid vs NSAID treatment in relation to
      trabeculectomy wound management. Eligible study participants will be randomized to receive
      either steroid or NSAID topical treatment one week post-trabeculectomy. Each group will dose
      with their assigned study treatment until three months post-trabeculectomy. Study
      participants will be followed for twelve months post-trabeculectomy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target IOP</measure>
    <time_frame>12 months</time_frame>
    <description>the proportion of patients achieving a target IOP range (≤21, ≤18, ≤15 or ≤12 mmHg) at 12 months post-operatively</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>NSAID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bromfenac 0.07% Oph Susp: used from one week post-op to three months post-op</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Steroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone: used from one week post-op to three months post-op</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac 0.07% Oph Susp</intervention_name>
    <description>Bromfenac 0.07% Oph Susp to be used post-operatively (week 1 to month 3) by one treatment group.</description>
    <arm_group_label>NSAID</arm_group_label>
    <other_name>Bromfenac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Topical dexamethasone to be used by all study participants for one week pre-trabeculectomy and by all study participants for one week post-trabeculectomy. At one week post-op, one of the treatment groups will continue to dose with dexamethasone.</description>
    <arm_group_label>Steroid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over the age of 18 years

          -  Uncontrolled open angle glaucoma

          -  Scheduled to undergo stand-alone trabeculectomy

          -  No previous incisional glaucoma surgery

          -  No ocular surgery of any kind in prior 6 months

        Exclusion Criteria:

          -  steroids and/or NSAIDs contraindicated

          -  poor corneal epithelial health
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cindy Hutnik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ivey Eye Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Coordinator</last_name>
    <phone>519.646.6100</phone>
    <phone_ext>66272</phone_ext>
    <email>rboyd24@uwo.ca</email>
  </overall_contact>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 16, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ivey Eye Institute</investigator_affiliation>
    <investigator_full_name>Cindy Hutnik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

